Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-25-268116
Filing Date
2025-11-06
Accepted
2025-11-06 07:53:16
Documents
62
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q sln-20250930.htm   iXBRL 10-Q 2137227
2 EX-31.1 sln-ex31_1.htm EX-31.1 15981
3 EX-31.2 sln-ex31_2.htm EX-31.2 15845
4 EX-32.1 sln-ex32_1.htm EX-32.1 10365
  Complete submission text file 0001193125-25-268116.txt   7300704

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sln-20250930.xsd EX-101.SCH 719123
64 EXTRACTED XBRL INSTANCE DOCUMENT sln-20250930_htm.xml XML 1320158
Mailing Address 12 HAMMERSMITH GROVE OFFICE 205 LONDON United Kingdom W6 7AP
Business Address 12 HAMMERSMITH GROVE OFFICE 205 LONDON United Kingdom W6 7AP 44-0-20-3457 6900
Silence Therapeutics plc (Filer) CIK: 0001479615 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0
Type: 10-Q | Act: 34 | File No.: 001-39487 | Film No.: 251456230
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)